Trade Summary

Yesterday, Hansen Gwenn, serving as Chief Scientific Officer at Nurix Therapeutics, Inc. (NRIX), sold 3,214 shares at $16.65 per share, for a total transaction value of $53,498.00. Following this transaction, Hansen Gwenn now holds 120,399 shares of NRIX.

This sale represents a 3.00% decrease in Hansen Gwenn's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, April 30, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, April 30, 2026, meaning the disclosure happened on the same day as the trade.

Nurix Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.